Skip to main content
. Author manuscript; available in PMC: 2014 Apr 2.
Published in final edited form as: Cell Metab. 2013 Jul 2;18(1):130–143. doi: 10.1016/j.cmet.2013.06.013

Figure 5. see also Figures S4 and S5 and Table S4. AGXT2 modulates lipid homeostasis in zebrafish.

Figure 5

(A) Zebrafish embryos were injected with 2nL of a 400uM solution of a splice blocking agxt2 morpholino oligonucleotide (MO) or control MO. At 48 hpf, agxt2 MO injection resulted in morphants with both normal phenotype (upper right panel, “AGXT2 I”) and morphants with defective yolk sac extension and pericardial edema (lower left panel, “AGXT2 II”). (B) RT-PCR of agxt2 mRNA for control, AGXT2 I and AGXT2 II morphants at 48 hpf; the 300 nucleotide fragment is the WT agxt2 transcript and the 109 nucleotide fragment is the knocked-down (KD) agxt2 transcript. The relative extent of WT agxt2 expression, normalized to rpl13-α, was estimated from band intensities; data are presented as mean ± SD, *P<0.05 for comparison to control. (C) β-aminoisobutyric acid levels in control, AGXT2 I and AGXT2 II morphants at 48 hpf; data are presented as mean ± SD, *P<0.05 for comparison to control. (D) CE and (E) TAG levels for control, AGXT2 I and AGXT II larvae at 5 dpf; data are presented as mean ± SD, *P<0.05 for comparison to control, #P<0.05 for comparison to AGXT2 I. (F) For TAGs (solid circles) and CEs (hollow circles), plot of each metabolite’s association with rs37370 (AGXT2) in FHS on the x-axis versus the percent difference for each metabolite in AGXT I versus control zebrafish on the y-axis.